Financials data is unavailable for this security.
View more
Year on year Haleon PLC had little change in net income (from 1.06bn to 1.05bn) despite revenues that grew 4.09% from 10.86bn to 11.30bn.
Gross margin | 61.56% |
---|---|
Net profit margin | 10.08% |
Operating margin | 17.82% |
Return on assets | 3.36% |
---|---|
Return on equity | 6.58% |
Return on investment | 4.00% |
More ▼
Cash flow in GBPView more
In 2023, Haleon PLC increased its cash reserves by 62.68%, or 383.00m. The company earned 2.10bn from its operations for a Cash Flow Margin of 18.58%. In addition the company used 134.00m on investing activities and also paid 1.57bn in financing cash flows.
Cash flow per share | 0.0203 |
---|---|
Price/Cash flow per share | 186.17 |
Book value per share | 1.82 |
---|---|
Tangible book value per share | -1.07 |
More ▼
Balance sheet in GBPView more
Current ratio | 0.8375 |
---|---|
Quick ratio | 0.5775 |
Total debt/total equity | 0.5336 |
---|---|
Total debt/total capital | 0.3465 |
More ▼
Growth rates in GBP
Year on year, growth in dividends per share increased 150.00% while earnings per share excluding extraordinary items fell by -1.29%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend.
Div yield(5 year avg) | -- |
---|---|
Div growth rate (5 year) | -- |
Payout ratio (TTM) | 35.66% |
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | -11.55 |
More ▼